Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Oncology 38

Oncology

pharma-news-for-sandoz-agios-organon-bms-sanofi-bayer-lilly

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data

Sandoz Launches generic Revlimid in 19 European Countries, Bringing a Flood of Competition to BMS' Megablockbuster Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, the company has been bracing for the day when the multiple myeloma superstar would face generic competition. Sandoz, a subsidiary of Novartis, announced on Friday that its generic version of the medication has been launched in 19 European countries. Stada Arzneimittel, a German generics manufacturer, has also launched its Revlimid generic in Europe. Lenalidomide will save patients money and also expand treatment options for patients with Multiple Myeloma, previously treated F...

Explore More...

FDA

FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan

Lung cancer infographic

Lung Cancer Infographic

150 Year Old Drug Indicates Potential of Future Cancer Therapy

The risk of solid cancer after chemotherapy

Companion Diagnostics

Notizia

INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER

Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug

Hot flashes

Notizia

Gene Therapy

Is Gene Therapy the Next Cancer Treatment Revolution?

FDA

Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray

Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand

LITT

The novel therapy for brain cancer treatments

Johnson & Johnson

Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner

Breast cancer

BREAST CANCER AWARENESS MONTH

Companion Diagnostics

Companion Diagnostics

transthyretin amyloidosis

Notizia

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly